Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Lenny Dang Clear advanced filters
  • A gain of function in the cancer-associated mutant of isocitrate dehydrogenase inspired protein engineering of Saccharomyces cerevisiae homoisocitrate dehydrogenase to create a 2-hydroxyadipate dehydrogenase. This neoactivity yields chirally pure (R)-2-hydroxyadipic acid, a synthetic precursor to the industrially valuable adipic acid used in pharmaceuticals and synthetic polymers.

    • Lenny Dang
    News & Views
    Nature Chemical Biology
    Volume: 8, P: 874-875
  • Squalene epoxidase (SQLE) is a key enzyme in cholesterol biosynthesis and is a target for hypercholesteremia and cancer drug development. Here the authors present the crystal structures of the human SQLE catalytic domain alone and bound with small molecule inhibitors, which will facilitate the development of next-generation SQLE inhibitors.

    • Anil K. Padyana
    • Stefan Gross
    • Gromoslaw A. Smolen
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-10
  • A small-molecule activator specific for PKM2 binds to a site distinct from the endogenous activator fructose-1,6-bisphosphate, promoting tetramerization and constitutive activation of PKM2, to inhibit xenograft tumor growth in mice.

    • Dimitrios Anastasiou
    • Yimin Yu
    • Matthew G Vander Heiden
    Research
    Nature Chemical Biology
    Volume: 8, P: 839-847
  • Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are commonly found in glioblastomas, a major subset of primary human brain cancers. However, only a single copy of the gene is mutated, suggesting that the mutation does not result in a simple loss of function. Here, IDH1 mutations are shown to act in a gain-of-function manner, resulting in a new ability of the enzyme to catalyse α-ketoglutarate to R(-)-2-hydroxyglutarate, an onco-metabolite.

    • Lenny Dang
    • David W. White
    • Shinsan M. Su
    Research
    Nature
    Volume: 462, P: 739-744